|
Saturday, April 29
8:00am–12:00pm
2180A—LWPES Plenary Session I
LWPES Plenary Session
Room 3007-3009, Moscone West
Chairs: Lynne Levitsky, Massachusetts General Hospital,
Boston, MA; Henry Anhalt, Saint Barnabas Medical Center,
Livingston, NJ; and Alan D. Rogol, University of Virginia,
Charlottesville, VA
Target Audience:
Endocrinologists, nephrologists, cardiologists, general
pediatricians, immunologists, geneticists and molecular
biologists.
-
Opening Remarks
Lynne L. Levitsky, Massachusetts General Hospital, Boston, MA
-
Lawson Wilkins Lecture:
Recent years have witnessed a
significant revision of the traditional view of fat cells
as simple stores of excess energy. Studies in the
speaker's lab as well as many others have clearly
demonstrated that adipocytes produce and regulate many
metabolic and hormonal signals, which generate profound
effects on systemic endocrine equilibrium. In his earlier
studies, he also demonstrated that these cells exhibit an
inflammatory capacity that is abnormal in obesity and key
to the pathogenesis of insulin resistance and diabetes.
Recently, he identified a key molecular mechanism
underlying the link between inflammatory responses and
insulin action. This pathway involves obesity-related
activation of the serine, threonine kinase, JNK, and the
consequent inhibition of insulin receptor signaling via
phosphorylation of a substrate of insulin receptor, IRS-1.
-
Integration of Metabolic and
Inflammatory Pathways in Metabolic Disease
Gokhan S. Hotamisligil, Harvard School of Public Health, Boston, MA
-
Robert Blizzard Lecture:
One of the greatest questions
asked of physicians caring for children with autoimmune
diabetes is "why did this happen?" This session
will unravel some of the mysteries surrounding the
etiology and pathogenesis of autoimmune diabetes from an
investigator who has dedicated his life to this issue.
-
On the Unravelling of the
Etiopathogenesis of Type 1 Diabetes: Are We Stuck or
Are We Winning?
Gian Franco Bottazzo, Ospedale Pediatrico Bambino Gesú, Scientific
Institute, Rome, Italy
-
Break
-
Esoterix Lecture:
The attendee will familiarize
him/herself with newer molecular mechanisms of growth
failure that are due to abnormalities in receptor and
post-receptor translation of GH signaling.
-
Molecular Mechanisms and Defects
in Growth Hormone Receptor Signaling
Peter Rotwein, Oregon Health and Science University, Portland, OR
10:30am–12:30pm
2310—Allergy, Immunology and Rheumatology
PAS Platform Session
Room 3000, Moscone West
Chairs: Mark Ballow and Diane Wara
12:00pm–3:00pm
2515—New Insights into the Pathogenesis and
Treatment of Asthma
PAS Mini Course
Room 3012, Moscone West
Chair: Ellen F. Crain, Albert Einstein College of Medicine,
Jacobi Medical Center, Bronx, NY
Target Audience: General
pediatricians, pulmonary medicine, genetics and allergists.
This mini course will highlight
new advances and developments in our understanding of
pediatric asthma and its treatment. Leading investigators will
present new information on the pharmacogenomics of asthma, the
roles of early environmental factors in the development of
asthma, advances in drug therapy, understanding of mechanisms
underlying the pathophysiology of asthma and insights into the
application of these advances to the care of children with
asthma.
-
Role of Pharmacogenomics in
Asthma Management
Michael Ephraim Wechsler, Harvard Medical School, Brigham and Women's
Hospital, Boston, MA
-
Early Environmental Factors in
the Development of Asthma
Fernando D. Martinez, Arizona Respiratory Center, The University of
Arizona, Tucson, AZ
-
Advances in Drug Treatment of
Asthma
Stanley J. Szefler, National Jewish Medical and Research Center,
University of Colorado Health Sciences Center, Denver, CO
-
Pathophysiology of Childhood
Asthma: Search for Mechanisms
Giuseppe N. Colasurdo, University of Texas-Houston Medical School,
Houston, TX
-
Epidemiology and Outcomes in
Asthma
Peter J. Gergen, National Institute of Allergy and Infectious Diseases
(NIAID), Bethesda, MD
1:00pm–3:00pm
2620—Neonatal Hematology–Immunology
PAS Poster Symposium
Room 3024, Moscone West
Chairs: Michael P. Sherman and Eric J. Werner
3:00pm–5:00pm
2710A—Hematopoietic Cell
Transplantation—An Update
ASPHO Symposium
Room 3016-3018, Moscone West
Chairs: Jakub Tolar and K. Scott Baker, University of
Minnesota, Minneapolis, MN
The program will begin with a
review of unrelated umbilical cord blood transplantation, now
a common practice in the treatment of pediatric malignancies.
The program will follow with a presentation of the most recent
data on reduced intensity hematopoietic cell transplantation
for treatment of malignant and non-malignant diseases in
children. The symposium will conclude with an overview of
immune implications of mesenchymal stem cell infusion,
including their use for graft versus host disease prophylaxis
and treatment. Cellular therapy has yielded notable successes
in the past decade and holds considerable promise, and one
should walk away from the session with a realistic overview of
the possibilities and limitations of cellular therapy for
childhood cancer.
After attending this session, it
is expected that the learner will be able to:
1. Identify efficacious cellular
therapy approaches.
2. Recognize the limitations of cellular therapy for childhood
cancer.
-
Introduction
Jakub Tolar, University of Minnesota, Minneapolis, MN
-
Umbilical Cord Blood
Transplantation: Current Practice and Future Innovations
John E. Wagner, University of Minnesota Medical School, Minneapolis, MN
-
Non-myeloablative Hematopoietic
Cell Transplantation in Children
Morris Kletzel, Northwestern University Feinberg School of Medicine,
Chicago, IL
-
Immunobiology of Mesenchymal Stem
Cells
Katarina Le Blanc, Karolinska University, Stockholm, Sweden
-
Question and Answer Session
3:15pm–5:15pm
2725—Integrating Genetic Susceptibility and
Environmental Influences in Pediatric Research
PAS Topic Symposium
Room 2008, Moscone West
Chair: Bruce P. Lanphear, Cincinnati Children's Environmental
Health Center, Cincinnati Children’s Hospital Medical
Center, Cincinnati, OH
Target Audience: A broad
pediatric audience with the goal of promoting
interdisciplinary understanding and greater integration of
genetic and environmental research.
Asthma, preterm birth, ADHD and
other prevalent pediatric conditions are widely recognized to
result from interactions of environmental influences and
genetic susceptibility. Tremendous progress has been made in
measuring both environmental and genetic risk factors.
Increasingly, researchers are moving beyond ecological methods
(e.g., questionnaires, air monitoring) to directly measure in
humans hundreds of environmental chemicals, from nicotine to
metals to DDT and phthalates. Similarly, unprecedented
innovation has led rapidly to high-throughput methods that
assess DNA variation across large cohorts. New
interdisciplinary collaborations that integrate state of the
art approaches to both environmental and genetic influences
should greatly improve our ability to predict and prevent
disease and disability. Such studies will be critical for
understanding mechanistic pathways, defining susceptible
subpopulations and developing effective interventions. This
session will provide an overview of gene–environment
research, describe recent advances in biomarkers of
environmental exposure and review new methods for measuring
genetic variability.
-
Gene–Environment Interaction in
Common Pediatric Conditions: Conceptual Overview and
Recent Evidence
Robert S. Kahn, Cincinnati Children’s Hospital Medical Center,
University of Cincinnati College of Medicine, Cincinnati,
OH
-
Advances in Biomarkers of
Environmental Exposure in Pediatric Research
Bruce P. Lanphear, Cincinnati Children's Environmental Health Center,
Cincinnati Children’s Hospital Medical Center,
Cincinnati, OH
-
Measuring Genetic Susceptibility
to the Environment: Study Designs and Genotyping Methods
Robert O. Wright, Harvard Children's Environmental Health Center,
Boston Children's Hospital and the Harvard School of
Public Health, Boston, MA
3:15pm–5:15pm
2735—Update on Therapeutic Monoclonal
Antibodies
PAS Topic Symposium
Room 3014, Moscone West
Chair: E. Richard Stiehm, UCLA School of Medicine, Los
Angeles, CA
Target Audience: Immunologists,
rheumatologists, hematologists, oncologists and general
pediatricians.
The first talk will be an
overview of the various therapeutic monoclonals and some
general principles of their use. Then a discussion of
Rituximab in refractory immune cytopenias and other disorders
will be presented. Then the use of anti-tumor necrosis factor
treatment including infliximab and adalimumab (Ramicade and
Humira) for rheumatic diseases in children. The final talk
will discuss the adverse effects of these therapies and some
projections for the future. Discussion will be held after each
presentation.
-
Overview
E. Richard Stiehm, Mattel Children's Hospital at UCLA, Los Angeles, CA
-
Use of Anti-CD20 (Rituximab) in
Hematology and Autoimmunity
James B. Bussel, New York Hospital, Cornell Medical Center, New York,
NY
-
Use of Anti-TNF and Other
Cytokine Inhibitors in Rheumatology and Related Illnesses
Christy Irene Sandborg, Stanford University Medical Center, Stanford,
CA
-
The Downside and Future of
Monoclonal Antibody Therapy
Susan Lee, University of California, San Diego, CA
Sunday, April 30
7:00am–8:00am
3035—Developmental Immunology: Scientific
Challenges and Opportunities
PAS Meet the Professor
Yerba Buena Gardens Salon 13, SF Marriott
This session will be informal and
designed to provide trainees and junior faculty with insight
and advice concerning the pursuit of an academic career that
includes research in developmental immunology. Current
scientific opportunities will be emphasized, including the
role of human versus rodent studies. Discussion will include
the challenges and potential rewards of having a "wet
lab" investigative career as part of an academic
pediatric position in immunology or infectious disease.
8:00am–10:00am
3100—Advances in Pathogenesis, Diagnosis
and Management of Kawasaki Disease
PAS/PIDS Topic Symposium
Room 3001, Moscone West
Chairs: Marian Melish, University of Hawaii, Kapiolani
Children's Hospital, Honolulu, HI; and Stanford T. Shulman,
Children's Memorial Hospital, Northwestern University,
Feinberg School of Medicine, Chicago, IL
Target Audience: Infectious
disease specialists, cardiologists, rheumatologists,
immunologists and primary care pediatricians.
Cloning the IgA antibody response
in acute Kawasaki Disease has led to exciting new insights
into the etiology and pathogenesis of this enigmatic illness.
The diagnosis of incomplete Kawasaki Disease remains a
significant clinical problem, and new guidelines have been
published to help the clinician in making this diagnosis.
Approximately 10–15% of children with acute Kawasaki Disease
do not respond to conventional intravenous gammaglobulin and
aspirin therapy, and new data regarding treatment with
steroids and Remicade are emerging. Knowledge regarding
optimal management of cardiac complications and long-term
outcome continues to evolve as patients diagnosed with
Kawasaki Disease in the 1970s and 1980s age.
-
Overview
Marian E. Melish, University of Hawaii, Kapiolani Children's Hospital,
Honolulu, HI
-
IgA Response in Acute Kawasaki
Disease Targets Inclusion Bodies in Acute Kawasaki Disease
Bronchial Epithelium
Anne H. Rowley, Northwestern University, Children's Memorial Hospital,
Chicago, IL
-
Clinical Dilemma of Diagnosing
Incomplete Kawasaki Disease
Jane C. Burns, University of California, San Diego, CA
-
Treatment of Refractory Kawasaki
Disease
Stanford T. Shulman, Children's Memorial Hospital, Northwestern
University, Feinberg School of Medicine, Chicago, IL
-
Management of Cardiac
Complications and Long-Term Outcome
Jane W. Newburger, Harvard University, Children’s Hospital of Boston,
Boston, MA
Sponsored jointly by
the Pediatric Infectious Diseases Society and the Pediatric
Academic Societies
11:00am–4:00pm
Commercial Exhibits Open and Posters
Available for Viewing
PAS Exhibits
Levels 1 and 2, Moscone West
Posters Available for Viewing:
11:00am–4:00pm
Author Attendance: 12:00pm–2:00pm
Level 1:
– Allergy, Immunology and Rheumatology
– Developmental-Behavioral Pediatrics
– Endocrinology
– Infectious Diseases
– General Pediatrics
– Hematology–Oncology
Level 2:
– Cardiology
– Neonatal Neurology
– Neonatology
12:00pm–2:00pm
Poster Session II
PAS Poster Session
Levels 1 and 2, Moscone West
Posters Available for Viewing:
11:00am–4:00pm
Author Attendance: 12:00pm–2:00pm
Level 1:
– Allergy, Immunology and Rheumatology
– Developmental-Behavioral Pediatrics
– Endocrinology
– Infectious Diseases
– General Pediatrics
– Hematology–Oncology
Level 2:
– Cardiology
– Neonatal Neurology
– Neonatology
Includes
-
SPR Fellow's Basic Research
Award: Myopalladin Mutations and Inherited
Cardiomyopathies
Enkhsaikhan Purevjav, Baylor College of Medicine, Houston, TX
-
SPR Clinical Research Award:
Accelerated Development in the Visual Areas of Preterm
Infants? A Voxel-Based Morphometry Study on Diffusion
Tensor MR Imaging (DTI)
Maria Miranda, Copenhagen University Hospital, Hvidovre, Denmark
-
SPR Fellow's Clinical Research
Award: Novel Genotyping Technology To Classify Childhood
Leukemia
Joshua D. Schiffman, Stanford University, Palo Alto, CA
-
SPR House Officer Research Award:
Erythropoietin Protein Expression in the Developing Human
Eye
Shrena Patel, University of New Mexico, Albuquerque, NM
2:00pm–4:00pm
3705—Infections at the
Maternal–Placental–Fetal Interface: Immunopathogenesis of
Group B Streptococcus, Listeria monocytogenes and
Cytomegalovirus
PAS/PIDS Topic Symposium
Room 3022-3024, Moscone West
Chairs: John R. Schreiber, University of Minnesota Medical
School and University of Minnesota Children's
Hospital/Fairview, Minneapolis, MN; and Robert F. Pass,
University of Alabama at Birmingham, Birmingham, AL
Target Audience: Neonatologists,
infectious disease specialists, immunologists, developmental
biologists and general pediatricians.
Infections in newborns commonly
result from acquisition either during the delivery process or
transplacentally. The host and pathogen factors that
contribute to acquisition of infections at the
maternal–placental–fetal interface are poorly understood.
This symposium will review the basic science and
immunopathogenesis of three diverse pathogens that all share
the ability to cause infections at the placental level:
cytomegalovirus, group B streptococcus, and Listeria
monocytogenes.
-
Intrauterine Cytomegalovirus
Infection, Transplacental Spread of Virus and Control by
Maternal Immunity
Lenore Pereira, University of California San Francisco, San Francisco,
CA
-
Host and Bacterial Factors in
Invasive Group B Streptococcal Infection
Craig E. Rubens, University of Washington, Seattle, WA
-
Listeriosis in the Pregnant
Guinea Pig: A Model of Vertical Transmission
Daniel A. Portnoy, University of California Berkeley, Berkeley, CA
-
Discussion
Sponsored jointly by
the Pediatric Infectious Diseases Society and the Pediatric
Academic Societies
4:15pm–5:45pm
3810—RNA Interference, Technological
Development of siRNAs and Potential Treatments for Childhood
Diseases
PAS State of the Art Plenary
Room 3016-3018, Moscone West
Chair: R. Alan B. Ezekowitz, Harvard Medical School,
Massachusetts General Hospital, Boston, MA
Target Audience: Basic scientists
studying a broad range of childhood diseases, translational
scientists of all disciplines studying clinical implications
of basic science research, clinical scientists studying
childhood and other diseases in need of improved therapies and
clinicians interested in cutting-edge science and its medical
implications.
RNA interference is a recently
discovered, naturally occurring intracellular process that
regulates gene expression through the silencing of specific
mRNAs. Methods of harnessing this natural pathway are being
developed that allow the catalytic degradation of targeted
mRNAs using specifically designed complementary small
inhibitory RNAs (siRNA). siRNAs are being chemically modified
to acquire drug-like properties. Numerous recent high-profile
publications have provided proofs of concept that RNA
interference may be useful therapeutically. Much of the design
of these siRNAs can be accomplished bioinformatically, thus
potentially expediting drug discovery and opening new avenues
of therapy for many childhood diseases including uncommon
pediatric and orphan diseases. A discussion of the science
behind RNA interference will be followed by a presentation of
the potential practical issues in applying this technology to
disease. The program then describes two therapeutic programs
currently under way with applications to pediatric diseases. A
question-and-answer time will follow each discussion.
-
The Science of RNA Interference
John J. Rossi, Beckman Research Institute of City of Hope, Duarte, CA
-
RNA Interference and Its
Potential Applications for Controlling Disease
Judy Lieberman, CBR Institute for Biomedical Research and Harvard
Medical School, Boston, MA
-
Silencing the VEGF Pathway with
siRNAs and the Potential Application to Retinopathy of
Prematurity
Pamela Pavco, Sirna Therapeutics, Boulder, CO
-
siRNA as Therapy for Respiratory
Syncytial Virus
John P. DeVincenzo, University of Tennessee School of Medicine,
Memphis, TN
4:15pm–6:15pm
3825A—Systemic Lupus: Implications of
Recent Developments for Management of Children with Lupus
Nephritis
ASPN Symposium
Room 2003-2005, Moscone West
Chairs: Joseph T. Flynn, Montefiore Medical Center, Bronx, NY;
and James Jarvis, University of Oklahoma Health Sciences
Center, Oklahoma City, OK
Target Audience: Nephrologists
and rheumatologists.
Glomerulonephritis remains a
significant source of morbidity in children with SLE. However,
recent changes in renal pathology and immunosuppressive
regimens offer the potential for improved outcomes in affected
children. This session will highlight some of the recent
advances in the diagnosis and treatment of children with lupus
nephritis.
-
Overview
Joseph T. Flynn, Children's Hospital at Montefiore, Bronx, NY
-
Lupus Nephritis: The
Rheumatologist's View
James N. Jarvis, University of Oklahoma Health Sciences Center,
Oklahoma City, OK
-
Updated WHO Classification
System: Are There Implications for Therapy?
Glen S. Markowitz, Columbia University Medical Center, New York, NY
-
Application of Monoclonal
Antibodies in Therapy: Rituximab and Beyond
Sangeeta Sule, Johns Hopkins University, Baltimore, MD
-
Cyclophosphamide Versus
Mycophenolate as Initial Therapy for Class III and IV
Lupus Nephritis
Ana L. Paredes, Miami Children's Hospital, Miami, FL
Sponsored jointly by
the AAP Section on Rheumatology and the American Society of
Pediatric Nephrology
4:15pm–6:15pm
3840—Cell Biology of Lung Disease
PAS Platform Session
Room 2004, Moscone West
Chairs: Michael M. Grunstein and Craig M. Schramm
4:15pm–6:15pm
3850—Human Milk and Breastfeeding
PAS Poster Symposium
Room 3001, Moscone West
Chairs: Sheela R. Geraghty and Ardythe L. Morrow
7:00pm–9:00pm
Preventing
Allergies— Preserving Quality of Life
PAS Industry Sponsored Symposium
Golden Gate Hall B1-2, SF Marriott
Target Audience:
Allergy/Immunologists, gastroenterologists, neonatologists.
Preventing Allergies –
Preserving Quality of Life, will focus on allergy issues in
the pediatric population and provide clinicians with valuable
information to help them understand the key contributing
factors behind the increase in allergic disease worldwide.
Faculty will present the hypothesis that childhood
sensitization to foods and allergens can lead to allergies in
later life.
The harmful effect that allergies
have on a child’s physical and emotional well-being and on
the family’s quality of life will also be thoroughly
discussed. The goal of treatment, therefore, is to prevent
allergies from developing.
One way to accomplish this goal
is to follow recommendations for proper nutrition in infants
and children. Exclusive breastfeeding for 4-6 months, use of
special formulas, and delayed introduction of solids are among
the methods to be discussed.
Clinicians attending this
symposium will learn new strategies for preventing infant and
childhood allergies that they can put into practice
immediately.
For registration information
please contact:
Haymarket Medical Continuing Education
Phone: (800) 636-1668
Email: preventingallergies@haymarketmedical.com
Supported by a grant from Nestle, USA
Tuesday, May 2
1:45pm–3:45pm
5725—Meet the Red Book Committee: Update on
New Vaccines
PAS/PIDS Hot Topic
Room 3014, Moscone West
Chairs: Sarah S. Long, Drexel University College of Medicine
and St. Christopher’s Hospital for Children, Philadelphia,
PA; Larry K. Pickering, Emory University School of Medicine,
Atlanta, GA; David Kimberlin, University of Alabama,
Birmingham, AL; and Henry Bernstein, Dartmouth Medical School,
Lebanon, NH
Target Audience: Primary care
pediatricians, infectious diseases physicians and adolescent
medicine physicians.
Vaccines represent the best
return on investment in health care resources. Currently, this
is a dynamic time for new vaccine development and licensure.
Recent changes in the vaccine schedule include the development
and licensure of new rotavirus vaccines, meningococcal
conjugate vaccines, acellular pertussis vaccines for use in
adolescents, papillomavirus, hepatitis A vaccines for
1-year-olds and a new “combination” vaccines (including
mumps-measles-rubella-varicella). Human papillomavirus vaccine
is expected to be licensed. To update physicians in practice,
the American Academy of Pediatrics will co-sponsor a symposium
on new vaccines, entitled “Red Book Update: New Vaccines”.
Topics to be discussed include
the newly licensed products listed above, as well as new
indications and uses of existing vaccines.
Sponsored jointly by
the Pediatric Infectious Diseases Society and the Pediatric
Academic Societies
|
